CL2022001314A1 - Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco - Google Patents

Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco

Info

Publication number
CL2022001314A1
CL2022001314A1 CL2022001314A CL2022001314A CL2022001314A1 CL 2022001314 A1 CL2022001314 A1 CL 2022001314A1 CL 2022001314 A CL2022001314 A CL 2022001314A CL 2022001314 A CL2022001314 A CL 2022001314A CL 2022001314 A1 CL2022001314 A1 CL 2022001314A1
Authority
CL
Chile
Prior art keywords
drug
prevention
treatment
cerebral hemorrhage
hemorrhage
Prior art date
Application number
CL2022001314A
Other languages
English (en)
Inventor
Tominaga Teiji
Niizuma Kuniyasu
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CL2022001314A1 publication Critical patent/CL2022001314A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un fármaco que se usa para el tratamiento o la prevención de una hemorragia cerebral, que incluye un compuesto de la fórmula (I) a continuación o una sal, éster o solvato farmacéuticamente aceptable de este, a modo de ingrediente activo.
CL2022001314A 2019-11-20 2022-05-19 Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco CL2022001314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019209932A JP7482618B2 (ja) 2019-11-20 2019-11-20 脳出血を治療又は予防するための薬剤及び該薬剤を用いて脳出血を治療又は予防する方法

Publications (1)

Publication Number Publication Date
CL2022001314A1 true CL2022001314A1 (es) 2023-03-17

Family

ID=75964094

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001314A CL2022001314A1 (es) 2019-11-20 2022-05-19 Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco

Country Status (6)

Country Link
US (2) US11850232B2 (es)
JP (1) JP7482618B2 (es)
AU (1) AU2020387174A1 (es)
CA (1) CA3158867A1 (es)
CL (1) CL2022001314A1 (es)
WO (1) WO2021100031A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023221797A1 (zh) * 2022-05-18 2023-11-23 四川科伦博泰生物医药股份有限公司 杂环化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4257026B2 (ja) 2000-08-31 2009-04-22 株式会社ティーティーシー トリプレニルフェノール化合物の選択的製造方法及びこれらの化合物の薬剤としての利用
WO2004002488A1 (ja) * 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. 脳出血治療剤
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
US7361493B1 (en) 2004-05-26 2008-04-22 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Production of urokinase in a three-dimensional cell culture
US20090270476A1 (en) 2005-10-06 2009-10-29 Keiji Hasumi Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof
WO2007094071A1 (ja) 2006-02-17 2007-08-23 Tokyo University Of Agriculture And Technology Tlo Co., Ltd. 肝機能改善剤
ES2728241T3 (es) * 2006-03-27 2019-10-23 Tms Co Ltd Proceso para la producción de compuestos de triprenilfenol
JP2008201688A (ja) 2007-02-16 2008-09-04 Tms Co Ltd 皮膚老化防止剤、化粧料及び皮膚外用剤
JP5224334B2 (ja) 2008-03-10 2013-07-03 農工大ティー・エル・オー株式会社 トリプレニルフェノール化合物及び血栓溶解促進剤
WO2011004620A1 (ja) * 2009-07-06 2011-01-13 国立大学法人東京農工大学 細胞保護剤

Also Published As

Publication number Publication date
US20240189280A1 (en) 2024-06-13
AU2020387174A1 (en) 2022-06-16
US11850232B2 (en) 2023-12-26
JP2021080216A (ja) 2021-05-27
JP7482618B2 (ja) 2024-05-15
WO2021100031A1 (ja) 2021-05-27
US20210322381A1 (en) 2021-10-21
CA3158867A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CO2022008344A2 (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
CR20160538A (es) Combinación
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
UY37941A (es) Derivados de bencimidazol y sus usos
CL2021000196A1 (es) Método de tratamiento de la epilepsia
SV2016005313A (es) Derivados de carboxamida
MX2016014946A (es) Derivados de carboxamida.
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CL2022001314A1 (es) Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
CO2022008209A2 (es) Compuesto que funciona como inhibidor de la quinasa del receptor de pdgf y composición
ECSP18023544A (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
CO2021010512A2 (es) Compuesto heterociclo pentacíclico
CL2016003271A1 (es) Métodos para tratar infecciones
AR100920A1 (es) Composiciones antimicrobianas con agentes efervescentes, método
ECSP22030740A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR117988A1 (es) Medicamento para profilaxis o tratamiento para la fibrosis pulmonar
BR112017027445A2 (pt) sistemas de liberação para liberação de fármaco controlada